Core Viewpoint - Arrowhead Pharmaceuticals, Inc. has filed a Complaint for Declaratory Judgment against Ionis Pharmaceuticals, Inc. to declare the invalidity of Ionis's U.S. Patent No. 9,593,333 and assert that Arrowhead's planned commercialization of investigational plozasiran does not infringe this patent [1] Company Summary - Arrowhead Pharmaceuticals is currently under FDA review for its investigational drug plozasiran [1] - The company intends to vigorously defend its position regarding the patent dispute with Ionis Pharmaceuticals [1] Industry Context - The legal action highlights ongoing patent disputes within the pharmaceutical industry, particularly concerning investigational drugs and their commercialization [1]

Core Insights - The company is preparing for a busy 6 to 9 months ahead, focusing on key clinical developments and transitions [2] Group 1: Clinical Developments - The company plans to bring MAPT, its first CNS drug administered via subcutaneous injection, to the clinic [2] - Following MAPT, the company will introduce its first dimer, the PCSK9 APOC3 dimer, which is expected to be a significant tool against atherosclerotic cardiovascular disease (ASCVD) [2] Group 2: Regulatory and Data Milestones - A major event is the PDUFA date for plozasiran in November, marking a transition from an R&D-only company to one that is also commercial [3] - The company anticipates data releases for INHBE and ALK7 related to obesity, with additional ALK7 data expected in the first half of 2026, approximately 6 months behind INHBE in dosing [3]